Calamos Wealth Management’s NovoCure NVCR Stock Holding History

Calamos Wealth Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-24,954	Closed	-$272K	–	547
2026 Q1	$272K	Buy	+24,954	New	+$312K	0.01%	456

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Calamos Wealth Management's NVCR Position: Q2 2026 in Review

Calamos Wealth Management sold out of NovoCure (NVCR) in Q2 2026, closing a stake of 24,954 shares — an estimated $272K sold.

Calamos Wealth Management first reported a position in NVCR in Q1 2026 and held it in 1 quarter. The position peaked at $272K in Q1 2026. 216 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Calamos Wealth Management reported no remaining NovoCure position as of Q2 2026 after selling out during the quarter.
Calamos Wealth Management sold 24,954 NovoCure shares in Q2 2026, an estimated $272K.
Calamos Wealth Management first reported a position in NovoCure in Q1 2026 and held it in 1 quarter.
Calamos Wealth Management's NovoCure position peaked at $272K in Q1 2026.
216 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Calamos Wealth Management's 13F filing for Q2 2026, filed 31 Jul 2026.